ES2072243T1 - Prueba de coagulacion cuantitativa respecto a factor vii activo. - Google Patents

Prueba de coagulacion cuantitativa respecto a factor vii activo.

Info

Publication number
ES2072243T1
ES2072243T1 ES92917364T ES92917364T ES2072243T1 ES 2072243 T1 ES2072243 T1 ES 2072243T1 ES 92917364 T ES92917364 T ES 92917364T ES 92917364 T ES92917364 T ES 92917364T ES 2072243 T1 ES2072243 T1 ES 2072243T1
Authority
ES
Spain
Prior art keywords
factor
assay
viia
factor viia
factor vii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES92917364T
Other languages
English (en)
Other versions
ES2072243T3 (es
Inventor
James J Morrissey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of ES2072243T1 publication Critical patent/ES2072243T1/es
Application granted granted Critical
Publication of ES2072243T3 publication Critical patent/ES2072243T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN ENSAYO PARA FACTOR VII (FACTOR VIIA) ACTIVADO HA SIDO DESARROLLADO USANDO FACTOR DE TEJIDO TRUNCADO (TF), UNA FORMA MUTANTE SOLUBLE DE FT QUE RETIENE LA FUNCION COFACTOR DEL TF HACIA EL FACTOR VIIA. TF DE LONGITUD TOTAL DIFERENTE, AUNQUE TTF APARECE NO PARA SOPORTAR LA CONVERSION DE FACTOR VII A VIIA. COMO RESULTADO , EL ENSAYO TTF PARA FACTOR VIIA ES LIBRE DE INTERFERENCIA DE FACTOR VII EN EL PLASMA Y ES POR CONSIGUIENTE ESPECIFICO PARA FACTOR VIIA. EL ENSAYO ES MUCHO MAS SIMPLE QUE LOS ENSAYOS EXISTENTES, YA QUE ES UN ENSAYO DE COAGULACION DE ETAPA UNICA REALIZADA CASI IDENTICAMENTE A ENSAYO DE PT. TAMBIEN ES CONSIDERABLEMENTE MAS SENSIBLE QUE LOS ENSAYOS ACTUALES PARA FACTOR VIIA EN EL PLASMA. YA QUE EL ENSAYO TTF SE CALIBRA CONTRA UNA NORMA DE FACTOR VIIAM SE PRODUCE UNA CONCENTRACION ABSOLUTA DE FACTOR VIIA EN NG/ML.
ES92917364T 1991-04-10 1992-04-09 Prueba de coagulacion cuantitativa para medir la concentracion de factor vii activo. Expired - Lifetime ES2072243T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/683,682 US5472850A (en) 1991-04-10 1991-04-10 Quantitative clotting assay for activated factor VII

Publications (2)

Publication Number Publication Date
ES2072243T1 true ES2072243T1 (es) 1995-07-16
ES2072243T3 ES2072243T3 (es) 2000-03-16

Family

ID=24745031

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917364T Expired - Lifetime ES2072243T3 (es) 1991-04-10 1992-04-09 Prueba de coagulacion cuantitativa para medir la concentracion de factor vii activo.

Country Status (10)

Country Link
US (3) US5472850A (es)
EP (1) EP0641443B1 (es)
JP (1) JP3047120B2 (es)
KR (1) KR940700679A (es)
AT (1) ATE185901T1 (es)
AU (1) AU663713B2 (es)
CA (1) CA2108282C (es)
DE (2) DE641443T1 (es)
ES (1) ES2072243T3 (es)
WO (1) WO1992018870A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
DE69224622T2 (de) * 1991-10-04 1998-11-05 Dade Behring, Inc., Deerfield, Ill. Herstellung von prothrombinzeit-reagenzien aus rekombinantem menschlichem gewebefaktor und sythetischen phospholipiden
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1994007515A1 (en) * 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
PL181102B1 (pl) * 1993-01-29 2001-05-31 Dahlbaeck Bjoern Sposób oznaczania w próbce funkcjonalnej aktywności wybranego składnika koagulacji krwi
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US5766869A (en) * 1995-11-30 1998-06-16 Ahs Hospital Corp. Factor V ratio blood test for susceptibility to thromboembolism
US5839443A (en) 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
PT988056E (pt) 1997-01-22 2003-09-30 Univ Texas Metodos e composicoes de factor tecidual para o tratamento da coagulacao e de tumores
DE19714559C1 (de) * 1997-04-09 1998-08-06 Blutspendedienst Der Drk Lande Verfahren zur Bestimmung von aktivierten Blutgerinnungsfaktoren in Plasma und Plasmaderivaten
CA2286164A1 (en) * 1997-04-09 1998-10-15 Gunter Wober Method for determining activated coagulation factors in plasma and plasma derivatives
CA2288058A1 (en) * 1997-04-23 1998-10-29 Instrumentation Laboratory, S.P.A. Recombinant rabbit tissue factor based prothrombin time reagent
DE19720853A1 (de) * 1997-05-17 1998-11-19 Dade Behring Marburg Gmbh Erhöhung der FVII Empfindlichkeit eines Thromboplastinreagenzes
US6245573B1 (en) 1998-02-12 2001-06-12 University Of Medicine And Dentistry Of New Jersey Rapid assessment of the coagulant activity of blood
DK1056884T3 (da) 1998-02-27 2002-02-25 Pamgene Bv Fremgangsmåde til ikke-specifik amplifikation af nukleinsyre
WO1999049803A1 (en) * 1998-04-01 1999-10-07 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
ATE274600T1 (de) 1998-06-08 2004-09-15 Univ Vermont Verfahren zur bestimmung der blutgerinnung in plasma
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
GB2358862B (en) * 1999-12-21 2004-07-21 Fermentron Ltd Processes for Extracting Carotenoids from Biomass Carotenoid Sources
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6743596B1 (en) * 2000-10-27 2004-06-01 Biomerieux, Inc. Method of determining global coagulability hemostatic potential
US6855509B2 (en) 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US7110118B2 (en) * 2000-12-19 2006-09-19 Trustees Of Boston University Spectral imaging for vertical sectioning
DE10064689B4 (de) * 2000-12-22 2004-08-05 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Verfahren zur Bestimmung der Blutzellhämostase
US6596543B2 (en) 2001-03-22 2003-07-22 Dade Behring Inc. Use of liposomes of defined composition and size for the preparation of prothrombin time reagents
EP1260817A3 (en) * 2001-05-08 2002-12-18 Warner-Lambert Company Method for direct measurement of coagulation factor VIIa activity in plasma
EP1409713B1 (en) * 2001-07-03 2013-03-20 Oklahoma Medical Research Foundation Assay for measuring factor viia-antithrombin complexes
US20030211075A1 (en) * 2001-09-27 2003-11-13 Thorpe Philip E. Combined compositions for tumor vasculature coagulation and treatment
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
US7604932B2 (en) * 2002-11-13 2009-10-20 Haematologic Technologies, Inc. Assay for tissue factor in a sample
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
EP2298287B1 (en) * 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
EP1853926A2 (en) * 2005-02-16 2007-11-14 The Board Of Trustees Of The University Of Illinois Procoagulants based on metal-chelating lipids
EP1869082B1 (en) * 2005-03-04 2011-04-13 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
FR2910969B1 (fr) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
WO2009046274A1 (en) * 2007-10-03 2009-04-09 The University Of Vermont And State Agriculture College Methods of detection of factor xia and tissue factor
WO2009046194A2 (en) * 2007-10-05 2009-04-09 The Board Of Trustees Of The University Of Illinois Fibrin sealant
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
DE102009048199A1 (de) * 2009-10-05 2011-04-21 Siemens Healthcare Diagnostics Products Gmbh Verfahren zur Bestimmung von Faktor XIII mit Hilfe von Referenzmaterial auf Plasmabasis
EP2494040B1 (en) 2009-10-30 2018-08-29 Aptevo BioTherapeutics LLC Method of producing recombinant vitamin k dependent proteins
WO2014019644A1 (en) * 2012-07-31 2014-02-06 Baxter International Inc. Selective measurement of active human protease coagulation factors
JP6844890B2 (ja) * 2016-01-07 2021-03-17 藤森工業株式会社 採血管、試薬及びそれらを利用した血液性状分析方法
JP6626761B2 (ja) * 2016-03-30 2019-12-25 シスメックス株式会社 プロトロンビン時間測定用試薬およびその製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479938A (en) * 1981-06-25 1984-10-30 Baxter Travenol Laboratories, Inc. Therapeutic composition containing factor VIIa
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
JPH0780783B2 (ja) * 1985-11-26 1995-08-30 ノボ ノルディスク アクティーゼルスカブ 出血障害の治療のための第▲ＶＩＩ▼ａ因子を含有する治療組成物
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
WO1988009817A1 (en) * 1987-06-12 1988-12-15 Mount Sinai School Of Medicine Of The City Univers Cloning and expression of human tissue factor
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Also Published As

Publication number Publication date
DE641443T1 (de) 1995-10-12
CA2108282C (en) 2003-09-09
DE69230183T2 (de) 2000-08-31
WO1992018870A1 (en) 1992-10-29
EP0641443B1 (en) 1999-10-20
US5750358A (en) 1998-05-12
ATE185901T1 (de) 1999-11-15
DE69230183D1 (de) 1999-11-25
KR940700679A (en) 1994-02-23
JP3047120B2 (ja) 2000-05-29
US5741658A (en) 1998-04-21
AU1872992A (en) 1992-11-17
JPH06506601A (ja) 1994-07-28
AU663713B2 (en) 1995-10-19
EP0641443A1 (en) 1995-03-08
ES2072243T3 (es) 2000-03-16
CA2108282A1 (en) 1992-10-11
US5472850A (en) 1995-12-05

Similar Documents

Publication Publication Date Title
ES2072243T1 (es) Prueba de coagulacion cuantitativa respecto a factor vii activo.
DK0420332T3 (da) Fremgangsmåde til bestemmelse af det endogene trombinpotentiale af plasma og blod, samt et kit til anvendelse ved fremgangsmåden
Barrett Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates.
Vásquez-Vivar et al. Superoxide anion formation from lucigenin: an electron spin resonance spin-trapping study
TWI256975B (en) Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
AU2001233785A1 (en) Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting
ES2255121T3 (es) Procedimiento para la determinacion del potencial anticoagulante de una muestra y procedimiento para la determinacion de la glicosilacion de trombomodulina.
AU621510B2 (en) Composition, device and method of assaying for a peroxidatively active substance
AR030650A1 (es) Tiras de prueba para detectar la presencia de un cofactor reducido en una muestra y metodos para utilizarlas
DK1151087T3 (da) Assay med mindsket baggrund
DK0690991T4 (da) Ny antikoagulant-cofaktor-aktivitet
ATE136331T1 (de) Kolorimetrische enzymatische analyse
DK173090A (da) Forbedrede ekstraktionsmetoder til fremstilling af thromboplastinreagenser
AU2003254642A1 (en) Hematological assay and kit
DE3473475D1 (en) Process for determining substrate or enzymatic activity
DK0567636T3 (da) Protein S kromogent assay
AU6385498A (en) Reagent for determining aptt
BRPI0016249A (pt) utilização de um substrato cromogênico e composição que permite a detecção de pelo menos uma cepa e/ou uma espécie de microorganismos.
Watazu et al. New automated measurement of mitochondrial aspartate aminotransferase with use of protease 401
NO980812L (no) Anvendelse av vanadiumbromperoksydase som et signalgenererende enzym for kjemilumineserende systemer, testkits og analytiske metoder
MY104675A (en) Chromogenic substrate for esterase and immunoassay using same.
ES2087892T3 (es) Utilizacion de la superoxido dismutasa en ensayos que implican una oxidasa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 641443

Country of ref document: ES